IDO1 and neoplasm: A clinical trial of the IDO1 inhibitor epacadostat in the treatment of melanoma, however, with or without pembrolizumab, an inhibitor of Programmed Death-1 (PD-1), failed to produce a significant reduction of tumour development [336].